Carregant...
Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
Alemtuzumab (previously known as Campath(®)) is a humanized monoclonal antibody directed against the CD52 antigen on mature lymphocytes that results in lymphopenia and subsequent modification of the immune repertoire. Here we explore evidence for its efficacy and safety in relapsing–remitting multip...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3593763/ https://ncbi.nlm.nih.gov/pubmed/23494602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S32687 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|